Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies

2.1 Trastuzumab deruxtecan (Enhertu, Daiichi-Sankyo) has a marketing authorisation as 'monotherapy for the treatment of adult patients with unresectable or metastatic HER2‑positive breast cancer who have received two or more prior anti‑HER2‑based regimens'.

2.2 The dosage schedule is available in the summary of product characteristics.

2.3 The company's list price is £1,455 per vial containing 100 mg powder for concentrate for solution for infusion (company's submission). The average cost of a course of treatment at list price is £117,857.55.

2.4 The company has a commercial arrangement. This makes trastuzumab deruxtecan available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.